Metabolism of tocotrienols in animals and synergistic inhibitory actions of tocotrienols with atorvastatin in cancer cells

Table 1 The levels of γ-T3 and its short-chain metabolites (γ-CEHC and γ-CMBHC) in serum, lung, liver, spleen, colon, and urine samples from mice treated with γ-T3

Sample name^a	γ-CEHC	γ-CMBHC	γ-T3
Serum (μM)	0.09 ± 0.03	0.12 ± 0.04	0.39 ± 0.07
Lung (μmol/kg)	0.06 ± 0.02	0.18 ± 0.02	0.92 ± 0.14
Liver (μmol/kg)	2.75 ± 0.50	15.32 ± 1.24	0.10 ± 0.01
Spleen (μmol/kg)	1.30 ± 0.34	0.37 ± 0.14	0.59 ± 0.07
Colon (μmol/kg)	5.49 ± 0.80	37.02 ± 4.97	0.60 ± 0.14
Urine (conjugated) (μM)	194.83 ± 29.45	28.12 ± 7.92	Not detected
Urine (free) (μM)	Not detected	0.14 ± 0.04	Not detected

^aSamples are from mice treated with AIN76m diet containing 0.05% γ-T3 for 2 weeks. Data are shown as mean ± S.E. (n = 5)

ISSN: 1865-3499